Virion Therapeutics raises $4M to continue work on cancer, viral infection treatments - Technical.ly Philly

Business

Sep. 17, 2018 9:37 am

Virion Therapeutics raises $4M to continue work on cancer, viral infection treatments

The Philly company, a spinout of the Wistar Institute, got backing from Robin Hood Ventures, Keiretsu Forum and Mid-Atlantic Bio Angels Group.

The Wistar Institute.

(Courtesy photo)

Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing.

The immunotherapy company is working on a path to commercialization for a set of vaccines aimed at treating certain types of cancers and chronic viral infections.

Cofounded by Wistar Institute professor Hildegund C.J. Ertl, Andrew Luber and Bernie Rudnick, the company is working on scientific assets that have been backed by some $25 million in grants.

The Philly-based company will use the funds to complete an FDA Investigational New Drug (IND) filing for its lead HPV vaccine candidate, and perform preclinical work on another vaccine for chronic HBV infection.

“We believe our checkpoint inhibitor has significant advantages over other agents in one of the most rapidly growing segments, immuno-oncology,” cofounder and CEO Rudnick said in a statement. “Our goals are to collaborate with major pharmaceutical companies in commercializing our vaccines, save lives and build a desirable business for near term exits with robust investment returns.”

Rudnick is also a member investor of Robin Hood Ventures, which joined the round with $417,000. Mid-Atlantic Bio Angels Group (MABA), Life Science Angels, Keiretsu Forum, Alliance of Angels and Crimson Peak also invested in the round, which the company expects will exceed $5 million upon final closing.

Investor Rena Rosenberg, a Robin Hood Ventures partner who co-led the Virion investment, said the experience of the company’s leadership made the case for the investment.

“If there is a team that is capable of identifying potential solutions in many of these infection-based cancers, this is the group of individuals that you want,” Rosenberg said.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Why this Radnor-based VC firm thinks impact investing is on the rise

Philly startups need more early-stage investments to compete

Carisma Therapeutics raised nearly $60M in Series A funding. Now what?

SPONSORED

Philly

Meet these 10 hiring companies at Super Meetup

Philadelphia

Linode

DevOps Engineer

Apply Now
Philadelphia

Linode

Chief Information Security Officer

Apply Now
Philadelphia

Perpay

UX Designer

Apply Now

A Center City biotech company is using an algorithm to help patients with memory loss

PA Biotech Center just announced a $50M investment fund and accelerator

Philly will host an inaugural pharma conference next month

SPONSORED

Philly

Verizon is looking for the brightest ideas on how to use its 5G technology

Chesterbrook, PA

Deacom

Inside Sales Representative

Apply Now
Horsham, PA

Penn Mutual

Product Owner/Business Transformation Specialist

Apply Now
Center City

Inspire

Member Experience Specialist

Apply Now

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!